Taking aim at hard-to-drug GPCRs with therapeutic antibodies

This is a preview of the full article that is published on Twist’s blog.

Immunotherapy has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the traditional immunization approach to therapeutic antibody discovery is severely limited in scale and throughput, making the development of antibodies targeting key receptor proteins both time-consuming and resource-intensive. 

High-quality synthetic antibody libraries can help overcome these hurdles by providing researchers with access to millions of antibodies that display a natural spectrum of variation, enabling rapid screening and optimization. 

Twist Biopharma, a division of Twist Bioscience, was built to do exactly that.  

By leveraging Twist Bioscience’s world-leading oligonucleotide synthesis platform to build high-quality antibody discovery libraries, Twist Biopharma is accelerating therapeutic discovery and development in many areas, including hard-to-drug targets. 

Emphasizing this point, Twist Biopharma recently announced the discovery and preclinical validation of optimized, fully-human, highly-potent antibody leads targeting two hard-to-drug receptors, ADORA2A and GLP1R.

Read the full post on Twist’s blog.